by Dinorah Castillo MSc | 09 May 2016
Systems toxicology is an important part of the research done at the Cube. It allows us to better understand the mechanisms of smoking related diseases, and use that information to assess the effects of switching to Reduced Risk Products (RRPs)* compared to continued smoking.
This year, as part of our efforts in making our research more visible, we have attended the SOT annual meeting, which is the largest in this field of science. More than 6,600 toxicologists from all around the world gathered at New Orleans on the 13th - 17th March to discuss and learn about the latest innovations in the field.
The event had a vast program and PMI R&D was represented by an important delegation. We organised an sbv Improver Symposium, presented at the electronic cigarette research session, and showed various posters during the ToxExpo.
At the sbv Improver Symposium we successfully presented the latest PMI results on our pre-clinical and clinical assessment studies. A Scientific Opinion panel was conducted in order to understand the opinion of toxicology experts and scientists on RRPs.
The 6 posters hosted at the ToxExpo were on different topics such as: Systems Biology & Toxicology, Tobacco Products, Emerging Technologies, and Respiratory Toxicology.
During the Electronic cigarette research platform session, 3 of our scientists explained ground-breaking results on the toxicity of heat-not-burn products.
PMI scientists talked about how they demonstrated that after a determined period of exposure to aerosol from platform 1 (Tobacco Heating System 2.2) the levels of compounds like aldehydes and carbon monoxide (CO) were reduced by over 90% and 98% respectively compared to cigarette smoke from a reference cigarette. During the evaluation of the endpoints recommended by the Organization for Economic Co-operation and Development (OECD), they were able to show a significant reduction in systemic & respiratory tract toxicity, as well as a lower degree of pulmonary inflammation. Overall, the analysis showed a reduced biological response of platform 1 on respiratory tissues compared with cigarette smoke from a reference cigarette.
The gold standard in developing RRPs is to approach as much as possible the effects observed in smoking cessation.
It is known that cigarette smoke is a risk factor for Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Disease (CVD). Using laboratory models, the impact that aerosol from platform 1 (Tobacco Heating System 2.2) has on these diseases was compared to cessation and cigarette smoke exposure. Multiple endpoints were analyzed. Contrary to cigarette smoke exposure, smoking cessation as well as switching to platform 1 (THS 2.2) exponentially decreased the rate of disease development as observed by histopathological and molecular endpoints.
Further detailed information on the different studies presented can be found on the SOT Annual Meeting on our events section.